Curigliano on the DESTINY-Breast06 Trial in HER2-Low and -Ultralow Metastatic Breast Cancer
Season 10, Episode 44, Jul 15, 06:00 PM
Dr Curigliano discusses the DESTINY-Breast06 trial of trastuzumab deruxtecan in patients with HER2-low or HER2-ultralow metastatic breast cancer.